Sou Hu Cai Jing·2025-08-23 22:29Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has reported a decline in its financial performance for the first half of 2025, with a focus on revenue and profit reductions, while also announcing a cash dividend distribution plan for shareholders [2][4]. Financial Performance Summary - For the first half of 2025, the company's main revenue was 1.304 billion yuan, a year-on-year decrease of 7.12% [2][6]. - The net profit attributable to shareholders was 211 million yuan, down 10.29% year-on-year [2][6]. - The net profit after deducting non-recurring gains and losses was 204 million yuan, a decline of 11.35% compared to the previous year [2][6]. - In Q2 2025, the company reported a single-quarter main revenue of 686 million yuan, a decrease of 9.57% year-on-year [2][6]. - The single-quarter net profit attributable to shareholders was 121 million yuan, down 12.33% year-on-year [2][6]. - The company's debt ratio stood at 18.14%, with investment income recorded at -28,700 yuan and financial expenses at 30.89 million yuan [2][6]. - The gross profit margin was reported at 70.17% [2][6]. Company Announcements Summary - The company’s subsidiary, Haohai Biological Technology Holdings Co., Ltd., has terminated its exclusive distribution agreement with Hengtai Optical and Hengtai Vision due to Hengtai Optical's acquisition by Carl Zeiss [3]. - As part of the termination agreement, Hengtai Optical's major shareholders will pay 80 million yuan as a termination compensation [3]. - Hengtai Vision reported total assets of 11.52 million yuan, net assets of 5.06 million yuan, and an operating income of 18.85 million yuan, with a net loss of 3.65 million yuan for the first half of 2025 [3]. - The company plans to increase market promotion for its self-developed OK lens products and optimize product structure [3]. - The cash dividend distribution plan for the first half of 2025 is set at 4.00 yuan per 10 shares (including tax), totaling 91.49 million yuan, which accounts for 43.35% of the net profit attributable to shareholders [4][6].